Literature DB >> 11741784

Synthesis of dipeptide-bound epoxides and alpha,beta-unsaturated amides as potential irreversible transglutaminase inhibitors.

Pierre de Macédo1, Claudio Marrano, Jeffrey W Keillor.   

Abstract

Herein we report the synthesis of 24 novel peptides as potential irreversible inactivators of transglutaminase (TGase). These peptides were designed to resemble Cbz-L-Gln-Gly, known to be a good TGase substrate, and to include either alpha,beta-unsaturated amide groups or the corresponding epoxide groups. The side chain length of the amino acid residue bearing the inhibitor group was also varied in order to permit investigation of this effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11741784     DOI: 10.1016/s0968-0896(01)00292-9

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

Review 1.  Therapeutic approaches for celiac disease.

Authors:  Nicholas M Plugis; Chaitan Khosla
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-05-09       Impact factor: 3.043

2.  Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles.

Authors:  R Edward Watts; Mathew Siegel; Chaitan Khosla
Journal:  J Med Chem       Date:  2006-12-14       Impact factor: 7.446

Review 3.  Novel therapies for coeliac disease.

Authors:  L M Sollid; C Khosla
Journal:  J Intern Med       Date:  2011-06       Impact factor: 8.989

4.  Structure-activity relationships of hydrophobic alkyl acrylamides as tissue transglutaminase inhibitors.

Authors:  Alana M M Rangaswamy; Pauline Navals; Eric W J Gates; Sammir Shad; Sarah K I Watt; Jeffrey W Keillor
Journal:  RSC Med Chem       Date:  2022-01-26

5.  Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.

Authors:  Abdullah Akbar; Nicole M R McNeil; Marie R Albert; Viviane Ta; Gautam Adhikary; Karine Bourgeois; Richard L Eckert; Jeffrey W Keillor
Journal:  J Med Chem       Date:  2017-09-14       Impact factor: 7.446

Review 6.  Immunopathogenesis and therapeutic approaches in pediatric celiac disease.

Authors:  Shreya Agarwal; Oormila Kovilam; Terence L Zach; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-04-01       Impact factor: 4.473

Review 7.  Transglutaminase 2 inhibitors and their therapeutic role in disease states.

Authors:  Matthew Siegel; Chaitan Khosla
Journal:  Pharmacol Ther       Date:  2007-05-13       Impact factor: 12.310

8.  Transglutaminase activation in neurodegenerative diseases.

Authors:  Thomas M Jeitner; Nancy A Muma; Kevin P Battaile; Arthur Jl Cooper
Journal:  Future Neurol       Date:  2009-07-01

9.  Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics.

Authors:  Hadil F Al-Jallad; Vamsee D Myneni; Sarah A Piercy-Kotb; Nicolas Chabot; Amina Mulani; Jeffrey W Keillor; Mari T Kaartinen
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

10.  Transglutaminase 2 in human diseases.

Authors:  Zsuzsa Szondy; Ilma Korponay-Szabó; Robert Király; Zsolt Sarang; Gregory J Tsay
Journal:  Biomedicine (Taipei)       Date:  2017-08-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.